A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)
Sponsor: Tanabe Pharma Corporation
A PHASE3 clinical study on Chronic Kidney Disease and Dialysis, this trial is completed. The trial is conducted by Tanabe Pharma Corporation and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tanabe Pharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ajka, Hungary , Alor Star, Malaysia , Arkhangelsk, Russia , Armavir, Russia , Baja, Hungary , Belgrade, Serbia , Budapest, Hungary , Chelyabinsk, Russia , Chernivtsi, Ukraine , Chita, Russia and 63 more locations